Yes, certainly.
The proposal with respect to subclause 4(2) specifically was that under the current legislation, a pharmaceutical manufacturer applying for a compulsory licence under CAMR--under the current legislation, not under Bill C-393--is required to include information about the version of the product, the quantity of the product to be exported, the name of the patent holder, the name of the importing country, and the name of the importing entity. I would like to restore the legislation. I would like to make sure that Bill C-393 reflects that requirement.